JP2019520326A - オキサボロールエステル及びその使用 - Google Patents
オキサボロールエステル及びその使用 Download PDFInfo
- Publication number
- JP2019520326A JP2019520326A JP2018559924A JP2018559924A JP2019520326A JP 2019520326 A JP2019520326 A JP 2019520326A JP 2018559924 A JP2018559924 A JP 2018559924A JP 2018559924 A JP2018559924 A JP 2018559924A JP 2019520326 A JP2019520326 A JP 2019520326A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- mmol
- methyl
- nmr
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Oxaborole ester Chemical class 0.000 title claims abstract description 199
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 52
- 201000010099 disease Diseases 0.000 claims abstract description 36
- 241000223109 Trypanosoma cruzi Species 0.000 claims abstract description 18
- 206010001935 American trypanosomiasis Diseases 0.000 claims abstract description 16
- 208000024699 Chagas disease Diseases 0.000 claims abstract description 15
- 201000002311 trypanosomiasis Diseases 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims description 424
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 149
- 229920006395 saturated elastomer Polymers 0.000 claims description 96
- 229910052757 nitrogen Inorganic materials 0.000 claims description 87
- 125000005842 heteroatom Chemical group 0.000 claims description 80
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 74
- 229910052760 oxygen Inorganic materials 0.000 claims description 74
- 239000001301 oxygen Substances 0.000 claims description 74
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 59
- 229910052717 sulfur Chemical group 0.000 claims description 59
- 239000011593 sulfur Chemical group 0.000 claims description 59
- 125000001931 aliphatic group Chemical group 0.000 claims description 52
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 50
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 48
- 229910052739 hydrogen Inorganic materials 0.000 claims description 44
- 239000001257 hydrogen Substances 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 38
- 229910052736 halogen Inorganic materials 0.000 claims description 33
- 229910052799 carbon Inorganic materials 0.000 claims description 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 29
- 125000000623 heterocyclic group Chemical group 0.000 claims description 21
- 125000001424 substituent group Chemical group 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 125000002950 monocyclic group Chemical group 0.000 claims description 17
- 125000002619 bicyclic group Chemical group 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 16
- 125000004429 atom Chemical group 0.000 claims description 12
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 8
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 claims description 4
- AUDHLQWLNVOGDC-IBGZPJMESA-N AN11736 Chemical compound CC(C)[C@H](NC(=O)C1=CC=C2COB(O)C2=C1C)C(=O)OCC1=CC=C(F)C=C1 AUDHLQWLNVOGDC-IBGZPJMESA-N 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 219
- 244000045947 parasite Species 0.000 abstract description 23
- 241001465754 Metazoa Species 0.000 abstract description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 251
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 219
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 186
- 239000000243 solution Substances 0.000 description 134
- 239000011541 reaction mixture Substances 0.000 description 112
- 230000002829 reductive effect Effects 0.000 description 105
- 235000019439 ethyl acetate Nutrition 0.000 description 101
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 98
- 239000007787 solid Substances 0.000 description 91
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 81
- SZXBQTSZISFIAO-ZETCQYMHSA-N (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C SZXBQTSZISFIAO-ZETCQYMHSA-N 0.000 description 76
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
- 239000011734 sodium Substances 0.000 description 68
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 59
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 47
- 238000004296 chiral HPLC Methods 0.000 description 47
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 46
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 46
- 239000002904 solvent Substances 0.000 description 46
- 239000012267 brine Substances 0.000 description 44
- 239000003921 oil Substances 0.000 description 41
- 235000019198 oils Nutrition 0.000 description 41
- 239000012044 organic layer Substances 0.000 description 41
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 238000006243 chemical reaction Methods 0.000 description 38
- 239000003208 petroleum Substances 0.000 description 38
- 238000004440 column chromatography Methods 0.000 description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 35
- 239000012299 nitrogen atmosphere Substances 0.000 description 35
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 30
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 29
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 238000000746 purification Methods 0.000 description 27
- 150000001413 amino acids Chemical group 0.000 description 26
- 238000004809 thin layer chromatography Methods 0.000 description 26
- GEZMEIHVFSWOCA-UHFFFAOYSA-N (4-fluorophenyl)methanol Chemical compound OCC1=CC=C(F)C=C1 GEZMEIHVFSWOCA-UHFFFAOYSA-N 0.000 description 24
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 24
- 238000002953 preparative HPLC Methods 0.000 description 24
- 239000002253 acid Substances 0.000 description 23
- 125000003118 aryl group Chemical group 0.000 description 23
- 125000001072 heteroaryl group Chemical group 0.000 description 22
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
- 150000001721 carbon Chemical group 0.000 description 21
- 239000002585 base Substances 0.000 description 20
- 239000012230 colorless oil Substances 0.000 description 20
- 239000000460 chlorine Substances 0.000 description 19
- 239000000706 filtrate Substances 0.000 description 19
- 239000000741 silica gel Substances 0.000 description 19
- 229910002027 silica gel Inorganic materials 0.000 description 19
- 229940024606 amino acid Drugs 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 18
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 17
- 229910052731 fluorine Inorganic materials 0.000 description 17
- 125000005843 halogen group Chemical group 0.000 description 17
- 239000012074 organic phase Substances 0.000 description 17
- 0 Cc1c(B(O)OC2)c2ccc1C(NC(*)(*)C(OI*)=O)=O Chemical compound Cc1c(B(O)OC2)c2ccc1C(NC(*)(*)C(OI*)=O)=O 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 229910010082 LiAlH Inorganic materials 0.000 description 16
- 238000001914 filtration Methods 0.000 description 16
- 239000011737 fluorine Substances 0.000 description 16
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 15
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical class [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 15
- XTIGGAHUZJWQMD-UHFFFAOYSA-N 1-chloro-2-methoxyethane Chemical compound COCCCl XTIGGAHUZJWQMD-UHFFFAOYSA-N 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical group CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 13
- 238000012746 preparative thin layer chromatography Methods 0.000 description 13
- UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 12
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 12
- 150000002367 halogens Chemical class 0.000 description 12
- 150000002430 hydrocarbons Chemical group 0.000 description 12
- 239000007858 starting material Substances 0.000 description 12
- 239000004698 Polyethylene Substances 0.000 description 11
- YIRBOOICRQFSOK-NSHDSACASA-N benzyl (2s)-2-amino-3-methylbutanoate Chemical compound CC(C)[C@H](N)C(=O)OCC1=CC=CC=C1 YIRBOOICRQFSOK-NSHDSACASA-N 0.000 description 11
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical group [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 241000282472 Canis lupus familiaris Species 0.000 description 10
- 239000007821 HATU Substances 0.000 description 10
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 10
- 229910004298 SiO 2 Inorganic materials 0.000 description 10
- 239000013058 crude material Substances 0.000 description 10
- 239000007791 liquid phase Substances 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 229940125782 compound 2 Drugs 0.000 description 9
- 125000001153 fluoro group Chemical group F* 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 125000004076 pyridyl group Chemical group 0.000 description 9
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 9
- 239000001476 sodium potassium tartrate Substances 0.000 description 9
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 239000012043 crude product Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- UWOTZNQZPLAURK-UHFFFAOYSA-N oxetane-3-carboxylic acid Chemical compound OC(=O)C1COC1 UWOTZNQZPLAURK-UHFFFAOYSA-N 0.000 description 8
- 239000012047 saturated solution Substances 0.000 description 8
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 7
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 208000030852 Parasitic disease Diseases 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 125000002947 alkylene group Chemical group 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- KJRCEJOSASVSRA-UHFFFAOYSA-N propane-2-thiol Chemical compound CC(C)S KJRCEJOSASVSRA-UHFFFAOYSA-N 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 5
- 125000006507 2,4-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(F)C(=C1[H])C([H])([H])* 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- CEMZBWPSKYISTN-YFKPBYRVSA-N methyl (2s)-2-amino-3-methylbutanoate Chemical compound COC(=O)[C@@H](N)C(C)C CEMZBWPSKYISTN-YFKPBYRVSA-N 0.000 description 5
- 125000002757 morpholinyl group Chemical group 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 125000003373 pyrazinyl group Chemical group 0.000 description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- SZVRVSZFEDIMFM-ZCFIWIBFSA-N (2s)-3-hydroxy-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)C(C)(C)O SZVRVSZFEDIMFM-ZCFIWIBFSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- NIJZBWHOHNWJBX-UHFFFAOYSA-N 2,4-difluorobenzyl alcohol 2,4-difluoro-1-(hydroxymethyl)benzene Chemical compound OCC1=CC=C(F)C=C1F NIJZBWHOHNWJBX-UHFFFAOYSA-N 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000223107 Trypanosoma congolense Species 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 4
- QRKNKDBJZVZQNE-OAHLLOKOSA-N (2r)-1,2-diphenylpropan-2-ol Chemical compound C([C@](O)(C)C=1C=CC=CC=1)C1=CC=CC=C1 QRKNKDBJZVZQNE-OAHLLOKOSA-N 0.000 description 3
- GNQLTCVBSGVGHC-UHFFFAOYSA-N (3,4-difluorophenyl)methanol Chemical compound OCC1=CC=C(F)C(F)=C1 GNQLTCVBSGVGHC-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 239000002841 Lewis acid Substances 0.000 description 3
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229960004001 benznidazole Drugs 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 3
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 125000005879 dioxolanyl group Chemical group 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 150000007517 lewis acids Chemical class 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 125000003566 oxetanyl group Chemical group 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 239000003880 polar aprotic solvent Substances 0.000 description 3
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 229960004295 valine Drugs 0.000 description 3
- 210000003501 vero cell Anatomy 0.000 description 3
- QRKNKDBJZVZQNE-HNNXBMFYSA-N (2s)-1,2-diphenylpropan-2-ol Chemical compound C([C@@](O)(C)C=1C=CC=CC=1)C1=CC=CC=C1 QRKNKDBJZVZQNE-HNNXBMFYSA-N 0.000 description 2
- ZYJPUMXJBDHSIF-NSHDSACASA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 description 2
- LLAKGSVMNLYWAQ-JEDNCBNOSA-N (2s)-3-methyl-2-(methylamino)butanoic acid;hydrochloride Chemical compound Cl.CN[C@@H](C(C)C)C(O)=O LLAKGSVMNLYWAQ-JEDNCBNOSA-N 0.000 description 2
- LLHOYOCAAURYRL-RITPCOANSA-N (2s,3r)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)OC(C)(C)C LLHOYOCAAURYRL-RITPCOANSA-N 0.000 description 2
- HZSRJBRQVGNLAT-MERQFXBCSA-N (3,4-difluorophenyl)methyl (2S)-2-amino-3-methylbutanoate hydrochloride Chemical compound Cl.CC(C)[C@H](N)C(=O)OCc1ccc(F)c(F)c1 HZSRJBRQVGNLAT-MERQFXBCSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- OJCNVBHXCGOWSA-SNVBAGLBSA-N (4-fluorophenyl)methyl (2S)-2-amino-3-hydroxy-3-methylbutanoate Chemical compound N[C@H](C(=O)OCC1=CC=C(C=C1)F)C(C)(C)O OJCNVBHXCGOWSA-SNVBAGLBSA-N 0.000 description 2
- WUZHLOGTWLZQGU-CYBMUJFWSA-N (4-fluorophenyl)methyl (2S)-3-hydroxy-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound C(C)(C)(C)OC(=O)N[C@H](C(=O)OCC1=CC=C(C=C1)F)C(C)(C)O WUZHLOGTWLZQGU-CYBMUJFWSA-N 0.000 description 2
- XELIWNAJNWXQAE-NSHDSACASA-N (4-fluorophenyl)methyl (2s)-2-amino-3-methylbutanoate Chemical compound CC(C)[C@H](N)C(=O)OCC1=CC=C(F)C=C1 XELIWNAJNWXQAE-NSHDSACASA-N 0.000 description 2
- LUECCFBGAJOLOX-UHFFFAOYSA-N (4-methylsulfonylphenyl)methanol Chemical compound CS(=O)(=O)C1=CC=C(CO)C=C1 LUECCFBGAJOLOX-UHFFFAOYSA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- PSQZJKGXDGNDFP-UHFFFAOYSA-N 2,2,3,3,3-pentafluoropropan-1-ol Chemical compound OCC(F)(F)C(F)(F)F PSQZJKGXDGNDFP-UHFFFAOYSA-N 0.000 description 2
- ZNOVTXRBGFNYRX-UHFFFAOYSA-N 2-[[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-UHFFFAOYSA-N 0.000 description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CULUWZNBISUWAS-UHFFFAOYSA-N Benznidazole Chemical compound [O-][N+](=O)C1=NC=CN1CC(=O)NCC1=CC=CC=C1 CULUWZNBISUWAS-UHFFFAOYSA-N 0.000 description 2
- 241000208199 Buxus sempervirens Species 0.000 description 2
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000012317 TBTU Substances 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 241000223095 Trypanosoma evansi Species 0.000 description 2
- 241000223099 Trypanosoma vivax Species 0.000 description 2
- JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 2
- LNMUKOSHOLHXJD-UHFFFAOYSA-N [5-fluoro-6-(trifluoromethyl)pyridin-3-yl]methanol Chemical compound FC=1C=C(C=NC=1C(F)(F)F)CO LNMUKOSHOLHXJD-UHFFFAOYSA-N 0.000 description 2
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000003349 alamar blue assay Methods 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- MKDLWJQJYMMDJR-JTQLQIEISA-N benzyl (2s)-2,5-diamino-5-oxopentanoate Chemical compound NC(=O)CC[C@H](N)C(=O)OCC1=CC=CC=C1 MKDLWJQJYMMDJR-JTQLQIEISA-N 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- 238000005885 boration reaction Methods 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000004452 carbocyclyl group Chemical group 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 2
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- CUGWNEOTLGLGDG-UHFFFAOYSA-N methyl 4-fluoro-3-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(F)C(O)=C1 CUGWNEOTLGLGDG-UHFFFAOYSA-N 0.000 description 2
- VSDUZFOSJDMAFZ-VIFPVBQESA-N methyl L-phenylalaninate Chemical compound COC(=O)[C@@H](N)CC1=CC=CC=C1 VSDUZFOSJDMAFZ-VIFPVBQESA-N 0.000 description 2
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- OHENQANLQNOMAO-UHFFFAOYSA-N oxaborole Chemical compound O1B=CC=C1 OHENQANLQNOMAO-UHFFFAOYSA-N 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 239000012026 peptide coupling reagents Substances 0.000 description 2
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 244000000040 protozoan parasite Species 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000003239 susceptibility assay Methods 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- KJZLJGZZDNGGCA-UHFFFAOYSA-N (1-methylpiperidin-4-yl)methanol Chemical compound CN1CCC(CO)CC1 KJZLJGZZDNGGCA-UHFFFAOYSA-N 0.000 description 1
- ZXWIRMDQZVGRAZ-ZETCQYMHSA-N (2-hydroxy-2-methylpropyl) (2S)-2-amino-3-methylbutanoate Chemical compound N[C@@H](C(C)C)C(=O)OCC(C)(C)O ZXWIRMDQZVGRAZ-ZETCQYMHSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- XOQZTHUXZWQXOK-SNVBAGLBSA-N (2r)-2-azaniumyl-5-phenylpentanoate Chemical compound [O-]C(=O)[C@H]([NH3+])CCCC1=CC=CC=C1 XOQZTHUXZWQXOK-SNVBAGLBSA-N 0.000 description 1
- SZXBQTSZISFIAO-SSDOTTSWSA-N (2r)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)[C@H](C(O)=O)NC(=O)OC(C)(C)C SZXBQTSZISFIAO-SSDOTTSWSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- HOBFSNNENNQQIU-JTQLQIEISA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylacetic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)C1=CC=CC=C1 HOBFSNNENNQQIU-JTQLQIEISA-N 0.000 description 1
- QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 1
- XOQZTHUXZWQXOK-JTQLQIEISA-N (2s)-2-amino-5-phenylpentanoic acid Chemical compound OC(=O)[C@@H](N)CCCC1=CC=CC=C1 XOQZTHUXZWQXOK-JTQLQIEISA-N 0.000 description 1
- OHDFGIXTRBDGRB-QMMMGPOBSA-N (2s)-2-cyclobutyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)C1CCC1 OHDFGIXTRBDGRB-QMMMGPOBSA-N 0.000 description 1
- WBSJQVRMQOLSAT-VIFPVBQESA-N (2s)-2-cyclopentyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)C1CCCC1 WBSJQVRMQOLSAT-VIFPVBQESA-N 0.000 description 1
- HRSFRSLKOPFWMZ-UHFFFAOYSA-N (3,4,5-trifluorophenyl)methanol Chemical compound OCC1=CC(F)=C(F)C(F)=C1 HRSFRSLKOPFWMZ-UHFFFAOYSA-N 0.000 description 1
- ZOHCHZKKZGFAQX-NSHDSACASA-N (3,4-difluorophenyl)methyl (2S)-2-amino-3-methylbutanoate Chemical compound N[C@@H](C(C)C)C(=O)OCC1=CC(=C(C=C1)F)F ZOHCHZKKZGFAQX-NSHDSACASA-N 0.000 description 1
- LOGIHEKXJKHXEC-UHFFFAOYSA-N (3,5-difluorophenyl)methanol Chemical compound OCC1=CC(F)=CC(F)=C1 LOGIHEKXJKHXEC-UHFFFAOYSA-N 0.000 description 1
- KRQHBUXUXOPOON-UHFFFAOYSA-N (3-chloro-4-fluorophenyl)methanol Chemical compound OCC1=CC=C(F)C(Cl)=C1 KRQHBUXUXOPOON-UHFFFAOYSA-N 0.000 description 1
- ZSRDNPVYGSFUMD-UHFFFAOYSA-N (3-chlorophenyl)methanol Chemical compound OCC1=CC=CC(Cl)=C1 ZSRDNPVYGSFUMD-UHFFFAOYSA-N 0.000 description 1
- FEEOCFWMUDMURN-QMMMGPOBSA-N (3-hydroxy-3-methylbutyl) (2S)-2-amino-3-methylbutanoate Chemical compound N[C@@H](C(C)C)C(=O)OCCC(C)(C)O FEEOCFWMUDMURN-QMMMGPOBSA-N 0.000 description 1
- XDPCNPCKDGQBAN-SCSAIBSYSA-N (3r)-oxolan-3-ol Chemical compound O[C@@H]1CCOC1 XDPCNPCKDGQBAN-SCSAIBSYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- XDPCNPCKDGQBAN-BYPYZUCNSA-N (3s)-oxolan-3-ol Chemical compound O[C@H]1CCOC1 XDPCNPCKDGQBAN-BYPYZUCNSA-N 0.000 description 1
- PTHGDVCPCZKZKR-UHFFFAOYSA-N (4-chlorophenyl)methanol Chemical compound OCC1=CC=C(Cl)C=C1 PTHGDVCPCZKZKR-UHFFFAOYSA-N 0.000 description 1
- SMDHYWIBSMMHTL-UHFFFAOYSA-N (4-fluorophenyl)methyl 3-aminooxetane-3-carboxylate Chemical compound NC1(COC1)C(=O)OCC1=CC=C(C=C1)F SMDHYWIBSMMHTL-UHFFFAOYSA-N 0.000 description 1
- MTXQKSQYMREAGJ-UHFFFAOYSA-N (4-methylsulfanylphenyl)methanol Chemical compound CSC1=CC=C(CO)C=C1 MTXQKSQYMREAGJ-UHFFFAOYSA-N 0.000 description 1
- WAPNOHKVXSQRPX-ZETCQYMHSA-N (S)-1-phenylethanol Chemical compound C[C@H](O)C1=CC=CC=C1 WAPNOHKVXSQRPX-ZETCQYMHSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- ZESKRVSPQJVIMH-UHFFFAOYSA-N 1,3-dimethoxypropan-2-ol Chemical compound COCC(O)COC ZESKRVSPQJVIMH-UHFFFAOYSA-N 0.000 description 1
- LJRCWNIWOVZLKS-UHFFFAOYSA-N 1,4-oxazepane;hydrochloride Chemical compound Cl.C1CNCCOC1 LJRCWNIWOVZLKS-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- FLRUNCJXOVYWDH-UHFFFAOYSA-N 1-(2-bromoethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CCBr)C=C1 FLRUNCJXOVYWDH-UHFFFAOYSA-N 0.000 description 1
- ROVVUKFHORPDSM-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonylamino]cyclobutane-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1(C(O)=O)CCC1 ROVVUKFHORPDSM-UHFFFAOYSA-N 0.000 description 1
- DSKCOVBHIFAJRI-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopropane-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1(C(O)=O)CC1 DSKCOVBHIFAJRI-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- OOWSDKUFKGVADH-UHFFFAOYSA-N 1-diphenylphosphoryloxy-2,3,4,5,6-pentafluorobenzene Chemical group FC1=C(F)C(F)=C(F)C(F)=C1OP(=O)(C=1C=CC=CC=1)C1=CC=CC=C1 OOWSDKUFKGVADH-UHFFFAOYSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical compound CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- UPQQXPKAYZYUKO-UHFFFAOYSA-N 2,2,2-trichloroacetamide Chemical compound OC(=N)C(Cl)(Cl)Cl UPQQXPKAYZYUKO-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- TVSLNRQODQRVJZ-UHFFFAOYSA-N 2-(3,4,5-trifluorophenyl)acetonitrile Chemical group FC1=CC(CC#N)=CC(F)=C1F TVSLNRQODQRVJZ-UHFFFAOYSA-N 0.000 description 1
- QHTUMQYGZQYEOZ-UHFFFAOYSA-N 2-(4-methylpiperazin-1-yl)ethanol Chemical compound CN1CCN(CCO)CC1 QHTUMQYGZQYEOZ-UHFFFAOYSA-N 0.000 description 1
- DBRMJCLTIHPLCZ-UHFFFAOYSA-N 2-(bromomethyl)quinoxaline Chemical compound C1=CC=CC2=NC(CBr)=CN=C21 DBRMJCLTIHPLCZ-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- ZHAKAIBZKYHXJS-UHFFFAOYSA-N 2-(chloromethyl)-1,3-thiazole Chemical compound ClCC1=NC=CS1 ZHAKAIBZKYHXJS-UHFFFAOYSA-N 0.000 description 1
- DDEAEWMDOSXKBX-UHFFFAOYSA-N 2-(chloromethyl)quinoline Chemical compound C1=CC=CC2=NC(CCl)=CC=C21 DDEAEWMDOSXKBX-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- NNTZJCLCBYUQFE-SECBINFHSA-N 2-morpholin-4-ylethyl (2S)-2-amino-3-hydroxy-3-methylbutanoate Chemical compound N[C@H](C(=O)OCCN1CCOCC1)C(C)(C)O NNTZJCLCBYUQFE-SECBINFHSA-N 0.000 description 1
- WUPWUPIKWAXSGE-UHFFFAOYSA-N 2-morpholin-4-ylethyl 3-aminooxetane-3-carboxylate Chemical compound NC1(COC1)C(=O)OCCN1CCOCC1 WUPWUPIKWAXSGE-UHFFFAOYSA-N 0.000 description 1
- HPJALMWOZYIZGE-UHFFFAOYSA-N 2-oxa-6-azaspiro[3.3]heptane Chemical compound C1NCC11COC1 HPJALMWOZYIZGE-UHFFFAOYSA-N 0.000 description 1
- RECARUFTCUAFPV-UHFFFAOYSA-N 2-oxa-7-azaspiro[3.5]nonane Chemical compound C1OCC11CCNCC1 RECARUFTCUAFPV-UHFFFAOYSA-N 0.000 description 1
- BXGYBSJAZFGIPX-UHFFFAOYSA-N 2-pyridin-2-ylethanol Chemical compound OCCC1=CC=CC=N1 BXGYBSJAZFGIPX-UHFFFAOYSA-N 0.000 description 1
- 125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- PCOFIIVWHXIDGT-UHFFFAOYSA-N 3-(hydroxymethyl)benzonitrile Chemical compound OCC1=CC=CC(C#N)=C1 PCOFIIVWHXIDGT-UHFFFAOYSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 1
- 125000000984 3-chloro-4-fluorobenzyl group Chemical group [H]C1=C(F)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 description 1
- OFCALSFZTOBZCI-UHFFFAOYSA-N 3-fluoro-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)C(C)(C)F OFCALSFZTOBZCI-UHFFFAOYSA-N 0.000 description 1
- QDHRSLFSDGCJFX-UHFFFAOYSA-N 3-fluorobenzyl alcohol Chemical compound OCC1=CC=CC(F)=C1 QDHRSLFSDGCJFX-UHFFFAOYSA-N 0.000 description 1
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 1
- VFXWFNIXCTUDAL-NSHDSACASA-N 3-morpholin-4-ylpropyl (2S)-2-amino-3-methylbutanoate Chemical compound N[C@@H](C(C)C)C(=O)OCCCN1CCOCC1 VFXWFNIXCTUDAL-NSHDSACASA-N 0.000 description 1
- 125000006500 3-trifluoromethoxy benzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC(F)(F)F)=C1[H])C([H])([H])* 0.000 description 1
- 125000006495 3-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 description 1
- XTJZBCBHCPQASK-UHFFFAOYSA-N 4,4-difluorocyclohexan-1-ol Chemical compound OC1CCC(F)(F)CC1 XTJZBCBHCPQASK-UHFFFAOYSA-N 0.000 description 1
- LMOOYAKLEOGKJR-UHFFFAOYSA-N 4-(bromomethyl)oxane Chemical compound BrCC1CCOCC1 LMOOYAKLEOGKJR-UHFFFAOYSA-N 0.000 description 1
- QKWSLYINUYKIRF-UHFFFAOYSA-N 4-(chloromethyl)-1,3-thiazole Chemical compound ClCC1=CSC=N1 QKWSLYINUYKIRF-UHFFFAOYSA-N 0.000 description 1
- MOOUWXDQAUXZRG-UHFFFAOYSA-N 4-(trifluoromethyl)benzyl alcohol Chemical compound OCC1=CC=C(C(F)(F)F)C=C1 MOOUWXDQAUXZRG-UHFFFAOYSA-N 0.000 description 1
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- TYSPDLZOMUDHQZ-UHFFFAOYSA-N 4-chloro-6-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=CC(Cl)=NC=N1 TYSPDLZOMUDHQZ-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- XAASLEJRGFPHEV-UHFFFAOYSA-N 4-cyanobenzyl alcohol Chemical compound OCC1=CC=C(C#N)C=C1 XAASLEJRGFPHEV-UHFFFAOYSA-N 0.000 description 1
- 125000000173 4-trifluoromethoxy benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC(F)(F)F)C([H])([H])* 0.000 description 1
- 125000001318 4-trifluoromethylbenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(F)(F)F 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- UZAOOCPKYMGRHG-UHFFFAOYSA-N 5-(chloromethyl)-1,3-thiazole Chemical compound ClCC1=CN=CS1 UZAOOCPKYMGRHG-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- OEKXUEWGXWCENG-UHFFFAOYSA-N 5-bromo-2-chloro-3-fluoropyridine Chemical compound FC1=CC(Br)=CN=C1Cl OEKXUEWGXWCENG-UHFFFAOYSA-N 0.000 description 1
- CHYDKBRRNOWOAR-UHFFFAOYSA-N 5-fluoro-6-(trifluoromethyl)pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=C(C(F)(F)F)C(F)=C1 CHYDKBRRNOWOAR-UHFFFAOYSA-N 0.000 description 1
- QRAAOFYCPMCLIB-UHFFFAOYSA-N 5-fluoro-6-iodopyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=C(I)C(F)=C1 QRAAOFYCPMCLIB-UHFFFAOYSA-N 0.000 description 1
- ZIOYQUNKXJQXQY-UHFFFAOYSA-N 5-hydroxy-2-methylbenzoic acid Chemical compound CC1=CC=C(O)C=C1C(O)=O ZIOYQUNKXJQXQY-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- OBNGWZDUQKEARE-UHFFFAOYSA-N 6-(chloromethyl)quinoline Chemical compound N1=CC=CC2=CC(CCl)=CC=C21 OBNGWZDUQKEARE-UHFFFAOYSA-N 0.000 description 1
- YICIHICLGVXCGP-UHFFFAOYSA-N 6-chloro-5-fluoropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=C(Cl)C(F)=C1 YICIHICLGVXCGP-UHFFFAOYSA-N 0.000 description 1
- WDJAQSJMDRFZIX-UHFFFAOYSA-N 6-oxa-3-azabicyclo[3.1.1]heptane Chemical compound C1NCC2CC1O2 WDJAQSJMDRFZIX-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical class C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- PIGMDKJJXMFPRP-UHFFFAOYSA-N B1CCCCO1 Chemical compound B1CCCCO1 PIGMDKJJXMFPRP-UHFFFAOYSA-N 0.000 description 1
- JXYACYYPACQCDM-UHFFFAOYSA-N Benzyl glycinate Chemical compound NCC(=O)OCC1=CC=CC=C1 JXYACYYPACQCDM-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- PQNOGAVSPNIGOH-JLHYYAGUSA-N C/C(/OCc1ccccc1)=C\NC(c1ccc(COB2O)c2c1C)=O Chemical compound C/C(/OCc1ccccc1)=C\NC(c1ccc(COB2O)c2c1C)=O PQNOGAVSPNIGOH-JLHYYAGUSA-N 0.000 description 1
- SNSOITLHPXTQTJ-UHFFFAOYSA-N CC(C)C(C(O[IH]N1CCOCC1)=O)NC(c1c(C)c(B(O)OC2)c2cc1)=O Chemical compound CC(C)C(C(O[IH]N1CCOCC1)=O)NC(c1c(C)c(B(O)OC2)c2cc1)=O SNSOITLHPXTQTJ-UHFFFAOYSA-N 0.000 description 1
- NIYZOIDPHYIIFA-INIZCTEOSA-N CC(C)COC([C@H](C(C)C)NC(c1ccc(COB2O)c2c1C)=O)=O Chemical compound CC(C)COC([C@H](C(C)C)NC(c1ccc(COB2O)c2c1C)=O)=O NIYZOIDPHYIIFA-INIZCTEOSA-N 0.000 description 1
- JQPXRSOEWAOWPN-HNNXBMFYSA-N CC(C)[C@@H](C(OC(C)(C)C)=O)NC(c1ccc(COB2O)c2c1C)=O Chemical compound CC(C)[C@@H](C(OC(C)(C)C)=O)NC(c1ccc(COB2O)c2c1C)=O JQPXRSOEWAOWPN-HNNXBMFYSA-N 0.000 description 1
- OYKQCFYANKEECD-HNNXBMFYSA-N CC(C)[C@@H](C(OCC(C)(C)O)=O)NC(c1ccc(COB2O)c2c1C)=O Chemical compound CC(C)[C@@H](C(OCC(C)(C)O)=O)NC(c1ccc(COB2O)c2c1C)=O OYKQCFYANKEECD-HNNXBMFYSA-N 0.000 description 1
- YTOQRCZQZLRAHA-PBHICJAKSA-N CC(C)[C@@H](C(OC[C@@H]1OCCC1)=O)NC(c1ccc(COB2O)c2c1C)=O Chemical compound CC(C)[C@@H](C(OC[C@@H]1OCCC1)=O)NC(c1ccc(COB2O)c2c1C)=O YTOQRCZQZLRAHA-PBHICJAKSA-N 0.000 description 1
- UENLVKQEUJDBGK-DEOSSOPVSA-N CC(C)[C@@H](C(OCc(cc1)ccc1C(N(C)CCN(C)C)=O)=O)NC(c1ccc(COB2O)c2c1C)=O Chemical compound CC(C)[C@@H](C(OCc(cc1)ccc1C(N(C)CCN(C)C)=O)=O)NC(c1ccc(COB2O)c2c1C)=O UENLVKQEUJDBGK-DEOSSOPVSA-N 0.000 description 1
- YUUKKZWLDDNPDW-YBEBCVOYSA-N CC(C)[C@@H](C(OCc(cc1)ccc1F)=O)NC(C1=CC(C2)C2(COB2O)C2=C1C(F)F)=O Chemical compound CC(C)[C@@H](C(OCc(cc1)ccc1F)=O)NC(C1=CC(C2)C2(COB2O)C2=C1C(F)F)=O YUUKKZWLDDNPDW-YBEBCVOYSA-N 0.000 description 1
- ADJLDDNEIKFPJP-AWEZNQCLSA-N CC(C)[C@@H](C(OCc(cc1F)cc(F)c1F)=O)NC(OC(C)(C)C)=O Chemical compound CC(C)[C@@H](C(OCc(cc1F)cc(F)c1F)=O)NC(OC(C)(C)C)=O ADJLDDNEIKFPJP-AWEZNQCLSA-N 0.000 description 1
- JWPXBPNPYRRRBI-IBGZPJMESA-N CC(C)[C@@H](C(OCc(cc1F)cc(F)c1F)=O)NC(c1ccc(COB2O)c2c1C)=O Chemical compound CC(C)[C@@H](C(OCc(cc1F)cc(F)c1F)=O)NC(c1ccc(COB2O)c2c1C)=O JWPXBPNPYRRRBI-IBGZPJMESA-N 0.000 description 1
- NZHCUDXTQBMITN-SANMLTNESA-N CC(C)[C@@H](C(OCc(cc1F)ccc1OCCCN1CCCC1)=O)NC(c1ccc(COB2O)c2c1C)=O Chemical compound CC(C)[C@@H](C(OCc(cc1F)ccc1OCCCN1CCCC1)=O)NC(c1ccc(COB2O)c2c1C)=O NZHCUDXTQBMITN-SANMLTNESA-N 0.000 description 1
- LLHOYOCAAURYRL-GDVGLLTNSA-N CC([C@@H](C(O)=O)NC(OC(C)(C)C)=O)O Chemical compound CC([C@@H](C(O)=O)NC(OC(C)(C)C)=O)O LLHOYOCAAURYRL-GDVGLLTNSA-N 0.000 description 1
- SFFUWZGFGYUCMC-NSHDSACASA-N COC(C[C@@H](C(OC)=O)NC(c1ccc(COB2O)c2c1)=O)=O Chemical compound COC(C[C@@H](C(OC)=O)NC(c1ccc(COB2O)c2c1)=O)=O SFFUWZGFGYUCMC-NSHDSACASA-N 0.000 description 1
- MWQXWJGUXZEMIE-INIZCTEOSA-N COC([C@H](Cc(cc1)ccc1O)NC(c1ccc(COB2O)c2c1)=O)=O Chemical compound COC([C@H](Cc(cc1)ccc1O)NC(c1ccc(COB2O)c2c1)=O)=O MWQXWJGUXZEMIE-INIZCTEOSA-N 0.000 description 1
- HFOWGBVUMSOEKA-INIZCTEOSA-N COC([C@H](Cc1ccccc1)NC(c1ccc(COB2O)c2c1)=O)=O Chemical compound COC([C@H](Cc1ccccc1)NC(c1ccc(COB2O)c2c1)=O)=O HFOWGBVUMSOEKA-INIZCTEOSA-N 0.000 description 1
- UCOJKDQJOVWXRE-UHFFFAOYSA-N COC(c(cc1)cc(C#N)c1F)=O Chemical compound COC(c(cc1)cc(C#N)c1F)=O UCOJKDQJOVWXRE-UHFFFAOYSA-N 0.000 description 1
- SXKGOKAHKBKTPB-UHFFFAOYSA-N COC(c(cc1)cc(C#N)c1S(C)(=O)=O)=O Chemical compound COC(c(cc1)cc(C#N)c1S(C)(=O)=O)=O SXKGOKAHKBKTPB-UHFFFAOYSA-N 0.000 description 1
- PUGWCWLVAPXDJF-UHFFFAOYSA-N COC(c(cc1)cc(C#N)c1SC)=O Chemical compound COC(c(cc1)cc(C#N)c1SC)=O PUGWCWLVAPXDJF-UHFFFAOYSA-N 0.000 description 1
- GKMWBESUDHZUML-GFCCVEGCSA-N C[C@H](CNC(OC(C)(C)C)=O)OCc1ccccc1 Chemical compound C[C@H](CNC(OC(C)(C)C)=O)OCc1ccccc1 GKMWBESUDHZUML-GFCCVEGCSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZTSBJPPJOQMCSX-UHFFFAOYSA-N Cc1c(B(O)OC2)c2ccc1C(NC1(COC1)C(OCCN1CCOCC1)=O)=O Chemical compound Cc1c(B(O)OC2)c2ccc1C(NC1(COC1)C(OCCN1CCOCC1)=O)=O ZTSBJPPJOQMCSX-UHFFFAOYSA-N 0.000 description 1
- RQALMEOGZLHIHU-UHFFFAOYSA-N Cc1c(B(O)OC2)c2ccc1C(NC1(COC1)C(OCc(cc1)ccc1F)=O)=O Chemical compound Cc1c(B(O)OC2)c2ccc1C(NC1(COC1)C(OCc(cc1)ccc1F)=O)=O RQALMEOGZLHIHU-UHFFFAOYSA-N 0.000 description 1
- 208000000425 Chagas Cardiomyopathy Diseases 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 240000001414 Eucalyptus viminalis Species 0.000 description 1
- YOGLKINOZKCUTL-UHFFFAOYSA-N FC1(CCC(CS)CC1)F Chemical compound FC1(CCC(CS)CC1)F YOGLKINOZKCUTL-UHFFFAOYSA-N 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- MPEKZIYOLQCWLL-UHFFFAOYSA-N Fc(cc(CBr)cc1F)c1F Chemical compound Fc(cc(CBr)cc1F)c1F MPEKZIYOLQCWLL-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- BQHPUNHVLODKKV-UHFFFAOYSA-N OCc(cc1C(C2)=O)ccc1S2(=O)=O Chemical compound OCc(cc1C(C2)=O)ccc1S2(=O)=O BQHPUNHVLODKKV-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000193168 Solanum betaceum Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229920001777 Tupperware Polymers 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- CLBZODUXRLSDBJ-PWSUYJOCSA-N [(1R)-1-phenylethyl] (2S)-2-amino-3-methylbutanoate Chemical compound N[C@@H](C(C)C)C(=O)O[C@H](C)C1=CC=CC=C1 CLBZODUXRLSDBJ-PWSUYJOCSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- CLBZODUXRLSDBJ-JQWIXIFHSA-N [(1s)-1-phenylethyl] (2s)-2-amino-3-methylbutanoate Chemical compound CC(C)[C@H](N)C(=O)O[C@@H](C)C1=CC=CC=C1 CLBZODUXRLSDBJ-JQWIXIFHSA-N 0.000 description 1
- RNVYQYLELCKWAN-RXMQYKEDSA-N [(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]methanol Chemical compound CC1(C)OC[C@@H](CO)O1 RNVYQYLELCKWAN-RXMQYKEDSA-N 0.000 description 1
- RNVYQYLELCKWAN-YFKPBYRVSA-N [(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]methanol Chemical compound CC1(C)OC[C@H](CO)O1 RNVYQYLELCKWAN-YFKPBYRVSA-N 0.000 description 1
- XRGSSROOYSFMMS-UHFFFAOYSA-N [3-(trifluoromethoxy)phenyl]methanol Chemical compound OCC1=CC=CC(OC(F)(F)F)=C1 XRGSSROOYSFMMS-UHFFFAOYSA-N 0.000 description 1
- BXEHKCUWIODEDE-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]methanol Chemical compound OCC1=CC=CC(C(F)(F)F)=C1 BXEHKCUWIODEDE-UHFFFAOYSA-N 0.000 description 1
- MWVQMAWLNHACQK-UHFFFAOYSA-N [4-(morpholin-4-ylmethyl)phenyl]methanol Chemical compound C1=CC(CO)=CC=C1CN1CCOCC1 MWVQMAWLNHACQK-UHFFFAOYSA-N 0.000 description 1
- ZLSOZAOCYJDPKX-UHFFFAOYSA-N [4-(trifluoromethoxy)phenyl]methanol Chemical compound OCC1=CC=C(OC(F)(F)F)C=C1 ZLSOZAOCYJDPKX-UHFFFAOYSA-N 0.000 description 1
- DGBDVJVPBJMVDH-UHFFFAOYSA-N [4-fluoro-3-(trifluoromethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C(C(F)(F)F)=C1 DGBDVJVPBJMVDH-UHFFFAOYSA-N 0.000 description 1
- CBSXUFWMVOAHTK-UHFFFAOYSA-N [6-(trifluoromethyl)pyridin-3-yl]methanol Chemical compound OCC1=CC=C(C(F)(F)F)N=C1 CBSXUFWMVOAHTK-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000012271 agricultural production Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- YGYLYUIRSJSFJS-MRVPVSSYSA-N benzyl (2r)-2-aminopropanoate Chemical compound C[C@@H](N)C(=O)OCC1=CC=CC=C1 YGYLYUIRSJSFJS-MRVPVSSYSA-N 0.000 description 1
- CFEYNMWFKQPQMR-LLVKDONJSA-N benzyl (2s)-2-amino-3,3-dimethylbutanoate Chemical compound CC(C)(C)[C@H](N)C(=O)OCC1=CC=CC=C1 CFEYNMWFKQPQMR-LLVKDONJSA-N 0.000 description 1
- IIDNACBMUWTYIV-VIFPVBQESA-N benzyl (2s)-2-amino-3-hydroxypropanoate Chemical compound OC[C@H](N)C(=O)OCC1=CC=CC=C1 IIDNACBMUWTYIV-VIFPVBQESA-N 0.000 description 1
- FPRSPUHXEPWUBZ-HNNXBMFYSA-N benzyl (2s)-2-amino-3-phenylpropanoate Chemical compound C([C@H](N)C(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 FPRSPUHXEPWUBZ-HNNXBMFYSA-N 0.000 description 1
- MBRRYUQWSOODEO-LBPRGKRZSA-N benzyl (2s)-2-amino-4-methylpentanoate Chemical compound CC(C)C[C@H](N)C(=O)OCC1=CC=CC=C1 MBRRYUQWSOODEO-LBPRGKRZSA-N 0.000 description 1
- BVEZTLFYEZBHOB-NSHDSACASA-N benzyl (2s)-2-amino-4-methylsulfanylbutanoate Chemical compound CSCC[C@H](N)C(=O)OCC1=CC=CC=C1 BVEZTLFYEZBHOB-NSHDSACASA-N 0.000 description 1
- YGYLYUIRSJSFJS-QMMMGPOBSA-N benzyl (2s)-2-aminopropanoate Chemical compound C[C@H](N)C(=O)OCC1=CC=CC=C1 YGYLYUIRSJSFJS-QMMMGPOBSA-N 0.000 description 1
- VVCLBQFBKZQOAF-NSHDSACASA-N benzyl (2s)-pyrrolidine-2-carboxylate Chemical compound O=C([C@H]1NCCC1)OCC1=CC=CC=C1 VVCLBQFBKZQOAF-NSHDSACASA-N 0.000 description 1
- DPEATBWCWKCPRX-UHFFFAOYSA-N benzyl 2-amino-2-methylpropanoate Chemical compound CC(C)(N)C(=O)OCC1=CC=CC=C1 DPEATBWCWKCPRX-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 238000006795 borylation reaction Methods 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- AQNQQHJNRPDOQV-UHFFFAOYSA-N bromocyclohexane Chemical compound BrC1CCCCC1 AQNQQHJNRPDOQV-UHFFFAOYSA-N 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- XYZUWOHEILWUID-UHFFFAOYSA-N bromomethylcyclopentane Chemical compound BrCC1CCCC1 XYZUWOHEILWUID-UHFFFAOYSA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 1
- VSSAZBXXNIABDN-UHFFFAOYSA-N cyclohexylmethanol Chemical compound OCC1CCCCC1 VSSAZBXXNIABDN-UHFFFAOYSA-N 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- ZVLOITUKHJQJJJ-SECBINFHSA-N cyclopentylmethyl (2S)-2-amino-3-hydroxy-3-methylbutanoate Chemical compound N[C@H](C(=O)OCC1CCCC1)C(C)(C)O ZVLOITUKHJQJJJ-SECBINFHSA-N 0.000 description 1
- OBRZISGRMUAEKZ-JTQLQIEISA-N cyclopentylmethyl (2s)-2-amino-3-methylbutanoate Chemical compound CC(C)[C@H](N)C(=O)OCC1CCCC1 OBRZISGRMUAEKZ-JTQLQIEISA-N 0.000 description 1
- ANXNHANENTULID-UHFFFAOYSA-N cyclopentylmethyl 3-aminooxetane-3-carboxylate Chemical compound NC1(COC1)C(=O)OCC1CCCC1 ANXNHANENTULID-UHFFFAOYSA-N 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical group [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BYHXBBOSJKPUJL-BYPYZUCNSA-N dimethyl (2s)-2-aminobutanedioate Chemical compound COC(=O)C[C@H](N)C(=O)OC BYHXBBOSJKPUJL-BYPYZUCNSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XNYZHCFCZNMTFY-UHFFFAOYSA-N diminazene Chemical compound C1=CC(C(=N)N)=CC=C1N\N=N\C1=CC=C(C(N)=N)C=C1 XNYZHCFCZNMTFY-UHFFFAOYSA-N 0.000 description 1
- 229950007095 diminazene Drugs 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940074076 glycerol formal Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004405 heteroalkoxy group Chemical group 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- DWKPPFQULDPWHX-VKHMYHEASA-N l-alanyl ester Chemical compound COC(=O)[C@H](C)N DWKPPFQULDPWHX-VKHMYHEASA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- ANYSGBYRTLOUPO-UHFFFAOYSA-N lithium tetramethylpiperidide Chemical compound [Li]N1C(C)(C)CCCC1(C)C ANYSGBYRTLOUPO-UHFFFAOYSA-N 0.000 description 1
- DBTNVRCCIDISMV-UHFFFAOYSA-L lithium;magnesium;propane;dichloride Chemical compound [Li+].[Mg+2].[Cl-].[Cl-].C[CH-]C DBTNVRCCIDISMV-UHFFFAOYSA-L 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000003564 m-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(C#N)=C1[H])C([H])([H])* 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 125000005905 mesyloxy group Chemical group 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- GVTZTBHOYNXMKJ-INIZCTEOSA-N methyl (2s)-2-(benzylamino)-3-phenylpropanoate Chemical compound C([C@@H](C(=O)OC)NCC=1C=CC=CC=1)C1=CC=CC=C1 GVTZTBHOYNXMKJ-INIZCTEOSA-N 0.000 description 1
- FNMJQKSDSQUBJY-LURJTMIESA-N methyl (2s)-2-amino-3-cyclopropylpropanoate Chemical compound COC(=O)[C@@H](N)CC1CC1 FNMJQKSDSQUBJY-LURJTMIESA-N 0.000 description 1
- PKZCMYOGIKCTFK-SCSAIBSYSA-N methyl (2s)-2-amino-3-hydroxy-3-methylbutanoate Chemical compound COC(=O)[C@@H](N)C(C)(C)O PKZCMYOGIKCTFK-SCSAIBSYSA-N 0.000 description 1
- MFDSUVIUGDAHLU-QMMMGPOBSA-N methyl (2s)-2-amino-3-pyridin-4-ylpropanoate Chemical compound COC(=O)[C@@H](N)CC1=CC=NC=C1 MFDSUVIUGDAHLU-QMMMGPOBSA-N 0.000 description 1
- YXMMTUJDQTVJEN-RITPCOANSA-N methyl (2s,3r)-2-amino-3-methylpentanoate Chemical compound CC[C@@H](C)[C@H](N)C(=O)OC YXMMTUJDQTVJEN-RITPCOANSA-N 0.000 description 1
- JTAQRDQNFANUEK-UHFFFAOYSA-N methyl 1h-imidazole-2-carboxylate Chemical compound COC(=O)C1=NC=CN1 JTAQRDQNFANUEK-UHFFFAOYSA-N 0.000 description 1
- GQJCAQADCPTHKN-UHFFFAOYSA-N methyl 2,2-difluoro-2-fluorosulfonylacetate Chemical compound COC(=O)C(F)(F)S(F)(=O)=O GQJCAQADCPTHKN-UHFFFAOYSA-N 0.000 description 1
- ZSBIMTDWIGWJPW-UHFFFAOYSA-N methyl 3-chloro-4-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(O)C(Cl)=C1 ZSBIMTDWIGWJPW-UHFFFAOYSA-N 0.000 description 1
- IYUSGKSCDUJSKS-UHFFFAOYSA-N methyl 3-fluoro-4-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(O)C(F)=C1 IYUSGKSCDUJSKS-UHFFFAOYSA-N 0.000 description 1
- QNUQDDPNECMPAT-UHFFFAOYSA-N methyl 4-(2-morpholin-4-ylethoxy)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1OCCN1CCOCC1 QNUQDDPNECMPAT-UHFFFAOYSA-N 0.000 description 1
- JTYWGSFSTNIJTA-UHFFFAOYSA-N methyl 4-chloro-3-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(Cl)C(O)=C1 JTYWGSFSTNIJTA-UHFFFAOYSA-N 0.000 description 1
- XVMWJNLIVAVWME-UHFFFAOYSA-N methyl 5-fluoro-6-(trifluoromethyl)pyridine-3-carboxylate Chemical compound FC=1C(=NC=C(C(=O)OC)C=1)C(F)(F)F XVMWJNLIVAVWME-UHFFFAOYSA-N 0.000 description 1
- KDMTVIVGDHCOAH-UHFFFAOYSA-N methyl 6-chloro-5-fluoropyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(Cl)C(F)=C1 KDMTVIVGDHCOAH-UHFFFAOYSA-N 0.000 description 1
- TWUXBVMXSBEKHA-UHFFFAOYSA-N methyl 6-chloropyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(Cl)=N1 TWUXBVMXSBEKHA-UHFFFAOYSA-N 0.000 description 1
- QVDXUKJJGUSGLS-LURJTMIESA-N methyl L-leucinate Chemical compound COC(=O)[C@@H](N)CC(C)C QVDXUKJJGUSGLS-LURJTMIESA-N 0.000 description 1
- MWZPENIJLUWBSY-VIFPVBQESA-N methyl L-tyrosinate Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWZPENIJLUWBSY-VIFPVBQESA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 1
- FMASTMURQSHELY-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-3-methyl-n-[(2-methyl-1h-indol-4-yl)methyl]pyridine-4-carboxamide Chemical compound C1=CC=C2NC(C)=CC2=C1CN(C=1C(=CC(F)=CC=1)C)C(=O)C1=CC=NC=C1C FMASTMURQSHELY-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- QMLWSAXEQSBAAQ-UHFFFAOYSA-N oxetan-3-ol Chemical compound OC1COC1 QMLWSAXEQSBAAQ-UHFFFAOYSA-N 0.000 description 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 1
- SWYHWLFHDVMLHO-UHFFFAOYSA-N oxetan-3-ylmethanol Chemical compound OCC1COC1 SWYHWLFHDVMLHO-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 150000003053 piperidines Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical class [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- DNCAUDUJGKXYKJ-VIFPVBQESA-N pyrazin-2-ylmethyl (2S)-2-amino-3-methylbutanoate Chemical compound N[C@@H](C(C)C)C(=O)OCC1=NC=CN=C1 DNCAUDUJGKXYKJ-VIFPVBQESA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- XAEQMSMXXCGAFG-SECBINFHSA-N pyridin-2-ylmethyl (2S)-2-amino-3-hydroxy-3-methylbutanoate Chemical compound N[C@H](C(=O)OCC1=NC=CC=C1)C(C)(C)O XAEQMSMXXCGAFG-SECBINFHSA-N 0.000 description 1
- XWVHUOUJXQLTLL-JTQLQIEISA-N pyridin-2-ylmethyl (2S)-2-amino-3-methylbutanoate Chemical compound N[C@@H](C(C)C)C(=O)OCC1=NC=CC=C1 XWVHUOUJXQLTLL-JTQLQIEISA-N 0.000 description 1
- OUAVTRQZCSDYAX-UHFFFAOYSA-N pyridin-2-ylmethyl 3-aminooxetane-3-carboxylate Chemical compound NC1(COC1)C(=O)OCC1=NC=CC=C1 OUAVTRQZCSDYAX-UHFFFAOYSA-N 0.000 description 1
- NBMWGCAYPSFRKI-JTQLQIEISA-N pyridin-3-ylmethyl (2s)-2-amino-3-methylbutanoate Chemical compound CC(C)[C@H](N)C(=O)OCC1=CC=CN=C1 NBMWGCAYPSFRKI-JTQLQIEISA-N 0.000 description 1
- CZSOFGNRITUUGU-JTQLQIEISA-N pyridin-4-ylmethyl (2S)-2-amino-3-methylbutanoate Chemical compound N[C@@H](C(C)C)C(=O)OCC1=CC=NC=C1 CZSOFGNRITUUGU-JTQLQIEISA-N 0.000 description 1
- HAMAGKWXRRTWCJ-UHFFFAOYSA-N pyrido[2,3-b][1,4]oxazin-3-one Chemical compound C1=CN=C2OC(=O)C=NC2=C1 HAMAGKWXRRTWCJ-UHFFFAOYSA-N 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- RJBVJBGFJIHJSZ-ZETCQYMHSA-N tert-butyl (2s)-2-amino-3-methylbutanoate Chemical compound CC(C)[C@H](N)C(=O)OC(C)(C)C RJBVJBGFJIHJSZ-ZETCQYMHSA-N 0.000 description 1
- TZHVYFBSLOMRCU-YFKPBYRVSA-N tert-butyl (2s)-2-aminopropanoate Chemical compound C[C@H](N)C(=O)OC(C)(C)C TZHVYFBSLOMRCU-YFKPBYRVSA-N 0.000 description 1
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 1
- JHLVEBNWCCKSGY-UHFFFAOYSA-N tert-butyl n-methylcarbamate Chemical compound CNC(=O)OC(C)(C)C JHLVEBNWCCKSGY-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- YLGRTLMDMVAFNI-UHFFFAOYSA-N tributyl(prop-2-enyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)CC=C YLGRTLMDMVAFNI-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
R1は、水素又はC1−6脂肪族であり;
R1aは、水素又はC1−6脂肪族であるか;或いは
R1及びR1aは、これらが接続している炭素原子と一緒に選択されて、所望により置換された3−ないし6員のスピロ炭素環式環を形成し;
それぞれのR2は、独立に水素、−ハロゲン、−OR、−NO2、−CN、−SR、−N(R)2、−C(O)R、−C(O)OR、−S(O)R、−S(O)2R、−C(O)N(R)2、−SO2N(R)2、−OC(O)R、−N(R)C(O)R、−N(R)C(O)OR、−N(R)SO2R、−OC(O)N(R)2であるか、又はC1−6脂肪族、及び3−ないし6員の飽和又は部分的に不飽和の単環式カルボシクリルからなる群から選択される所望による置換基であり;
R3は、水素又は所望により置換されたC1−6脂肪族であり;
R4は、水素、天然又は非天然のアミノ酸側鎖基であるか、或いはC1−6脂肪族、3−ないし7員の飽和又は部分的に不飽和の単環式カルボシクリル、及びフェニルからなる群から選択される所望により置換された基であるか;或いは
R3及びR4は、R4に接続した炭素原子及びR3に接続した窒素原子と一緒に選択されて、所望により置換された、酸素、窒素、又は硫黄から選択される0−1個の更なる異種原子を有する3−ないし6員のヘテロシクリルを形成し;
R5は、水素又は所望により置換されたC1−6脂肪族であるか;或いは
R4及びR5は、これらが接続している炭素原子と一緒に選択されて、酸素、窒素、又は硫黄から選択される1−2個の異種原子を有する3−ないし6員のスピロ複素環式環、並びに3−ないし6員の飽和の又は部分的に不飽和の単環式スピロ炭素環式環から選択される、所望により置換された環を形成し;
Lは、共有結合であるか、又は所望により置換された、二価のC1−10飽和又は不飽和の、直鎖又は分枝鎖の炭化水素鎖であり、ここにおいて、Lの一つ、二つ又は三つのメチレン単位は、所望により、そして独立に−Cy−、−O−、−SO−、−SO2−、−C(O)−、−C(O)N(R)−、−S−、−N(R)−、−C(O)O−、−OC(O)−、−N(R)C(O)−、−N(R)SO2−、又は−SO2N(R)−によって置換され;
ここにおいて、それぞれの−Cy−は、フェニレン、3−ないし7員の飽和又は部分的に不飽和の単環式カルボシクリレン、酸素、窒素、又は硫黄から選択される1−2個の異種原子を有する3−ないし7員の飽和又は部分的に不飽和の単環式ヘテロシクリレン、酸素、窒素、又は硫黄から選択される1−4個の異種原子を有する5−ないし6員のへテロアリーレン、7−ないし10員の飽和又は部分的に不飽和の二環式カルボシクリレン、8−ないし10員の二環式アリーレン、酸素、窒素、又は硫黄から選択される1−4個の異種原子を有する7−ないし10員の飽和又は部分的に不飽和の二環式ヘテロシクリレン、及び酸素、窒素、又は硫黄から選択される1−4個の異種原子を有する7−ないし10員の二環式へテロアリーレンからなる群から選択される独立に所望により置換された二価の環であり;
R6は、水素、−ハロゲン、−OR、−NO2、−CN、−SR、−N(R)2、−C(O)R、−C(O)OR、−S(O)R、−S(O)2R、−C(O)N(R)2、−SO2N(R)2、−OC(O)R、−N(R)C(O)R、−N(R)C(O)OR、−N(R)SO2R、−OC(O)N(R)2、C1−6脂肪族、フェニル、酸素、窒素、又は硫黄から選択される1−2個の異種原子を有する3−ないし7員の飽和又は部分的に不飽和の単環式カルボシクリル、酸素、窒素、又は硫黄から選択される1−2個の異種原子を有する3−ないし7員の飽和又は部分的に不飽和の単環式ヘテロシクリル、酸素、窒素、又は硫黄から選択される1−4個の異種原子を有する5−ないし6員のヘテロアリール、
7−ないし10員の飽和又は部分的に不飽和の二環式カルボシクリル、8−ないし10員の二環式アリール、酸素、窒素、又は硫黄から選択される1−4個の異種原子を有する7−ないし10員の飽和又は部分的に不飽和の二環式ヘテロシクリル、酸素、窒素、又は硫黄から選択される1−4個の異種原子を有する7−ないし10員の二環式ヘテロアリール、並びに架橋された二環式からなる群から選択される所望により置換された基であり;
それぞれのRは、独立に水素又は所望により置換されたC1−6脂肪族であり;
ここにおいて、Lが共有結合である場合、R6は、−OR、−ハロゲン、−NO2、−CN、−SR、−N(R)2、−S(O)R、−S(O)2R、−SO2N(R)2、−OC(O)R、−N(R)C(O)R、−N(R)C(O)OR、−N(R)SO2R、又は−OC(O)N(R)2以外であり;そして
ここにおいて、Lが共有結合以外である場合、これは、O*と表示されたカルボキシルの酸素に結合する炭素原子を含む。
本発明の化合物は、一般的に先に記載したものを含み、そして更に本明細書中に開示される綱、亜綱、及び種によって例示される。本明細書中で使用する場合、他に示されない限り、以下の定義が適用されるべきである。本発明の目的のために、化学元素は、Handbook of Chemistry and Physics,75th EdのCAS versionの元素周期表により規定される。更に、有機化学の一般的な原理は、“Organic Chemistry”,Thomas Sorrell,University Science Books,Sausalito:1999,and “March’s Advanced Organic Chemistry”,5th Ed.,Ed.: Smith,M.B.and March,J.,John Wiley & Sons,New York:2001中に記載され、これらの全ての内容は、本明細書中に参考文献として援用される。
本明細書中で使用する、用語“二価のC1−10(又はC1−6、等)の飽和又は不飽和の、直鎖又は分枝鎖の炭化水素鎖”は、本明細書中に定義される直鎖又は分枝鎖である二価のアルキレン、アルケニレン、及びアルキニレン鎖を指す。
単独で或いは“アラルキル”、“アラルコキシ”、又は“アリールオキシアルキル”中のような大きい部分の一部として使用される用語“アリール”は、合計5から10個の環のメンバーを有する単環式及び二環式環系を指し、ここにおいて、系の少なくとも一つの環は、芳香族であり、そしてここにおいて、系のそれぞれの環は、3から7個の環のメンバーを含有する。用語“アリール”は、用語“アリール環”と互換的に使用することができる。幾つかの態様において、8−10員の二環式アリール基は、所望により置換されたナフチル環である。本発明のある態様において、“アリール”は、制約されるものではないが、フェニル、ビフェニル、ナフチル、アントラシル等を含む芳香族環系を指し、これらは、一つ又はそれより多い置換基を保有することができる。用語“アリール”の範囲内に更に含まれるものは、本明細書中で使用する場合、芳香族環が一つ又はそれより多い非芳香族環、例えばインダニル、フタリミジル、ナフチミジル、フェナントリジニル、又はテトラヒドロナフチル、等に縮合した基である。
C1−6脂肪族、−CH2Ph、−O(CH2)0−1Ph、−CH2−(5−6員のヘテロアリール環)、或いは窒素、酸素、又は硫黄から独立に選択される0−4個の異種原子を有する5−6員の飽和、部分的に不飽和、又はアリール環、或いは上記の定義に関わらず、その介在する原子(類)と一緒に選択されるR°の二つの独立の出現は、窒素、酸素、又は硫黄から独立に選択される0−4個の異種原子を有する3−12員の飽和、部分的に不飽和、又はアリールのモノ−又は二環式環を形成し、これらは、以下に定義ように置換されることができる。
以下の記号:
化合物
先に記載したように、ある態様において、提供される化合物は、以下の式I:
幾つかの態様において、R1及びR1aは、水素である。幾つかの態様において、R1及びR1aは、メチルである。
幾つかの態様において、R2は、所望により置換された3−ないし6員の飽和又は部分的に不飽和の単環式カルボシクリルである。幾つかの態様において、R2は、3−ないし6員の飽和の単環式カルボシクリルである。幾つかの態様において、R2は、シクロプロピルである。
幾つかの態様において、R2は、ハロゲンで置換されたC1−6脂肪族である。幾つかの態様において、R2は、−CH2F2又は−CF3である。幾つかの態様において、R2は、水素で置換されたC1−6脂肪族である。
幾つかの態様において、R4は、水素である。幾つかの態様において、R4は、天然の又は非天然のアミノ酸側鎖基である。
幾つかの態様において、R4は、フェニルである。幾つかの態様において、R4は、−OHで所望により置換されたフェニルである。
幾つかの態様において、R4は、−(CH2)mR7又は−CH(CH3)OCH2R7であり、ここにおいて、R7は、フェニル、8−ないし10員の二環式アリール、3−ないし7員の飽和又は部分的に不飽和の単環式カルボシクリル、酸素、窒素、又は硫黄から選択される1−2個の異種原子を有する3−ないし7員の飽和又は部分的に不飽和の単環式ヘテロシクリル、及び窒素、酸素、又は硫黄から独立に選択される1−4個の異種原子を有する5−ないし10員の単環式又は二環式ヘテロアリールからなる群から選択される所望により置換された環である。幾つかの態様において、R4は、−CH2R7であり、ここにおいて、R7は、所望により置換されたフェニルである。幾つかの態様において、R4は、−(CH2)2R7であり、ここにおいて、R7は、所望により置換されたフェニルである。幾つかの態様において、R4は、−(CH2)3R7であり、ここにおいて、R7は、所望により置換されたフェニルである。
R7は、C1−6脂肪族、フェニル、3−ないし7員の飽和又は部分的に不飽和の単環式カルボシクリル、酸素、窒素、又は硫黄から選択される1−2個の異種原子を有する3−ないし7員の飽和又は部分的に不飽和の単環式ヘテロシクリル、酸素、窒素、又は硫黄から選択される1−4個の異種原子を有する5−ないし6員のヘテロアリール、窒素、酸素、又は硫黄から独立に選択される1−4個の異種原子を有する5−ないし6員のヘテロアリール、7−ないし10員の飽和又は部分的に不飽和の二環式カルボシクリル、8−ないし10員の二環式アリール、酸素、窒素、又は硫黄から選択される1−4個の異種原子を有する7−ないし10員の飽和又は部分的に不飽和の二環式ヘテロシクリル、及び酸素、窒素、又は硫黄から選択される1−4個の異種原子を有する7−ないし10員の二環式ヘテロアリールからなる群から選択される所望により置換された群からなる群から選択される所望により置換された環であり、そしてmは、0、1、2、又は3から選択される。
幾つかの態様において、R4及びR5は、これらが接続している炭素原子と一緒に選択されて、酸素、窒素、又は硫黄から選択される1−2個の異種原子を有する所望により置換された3−ないし6員のスピロ複素環式環を形成する。一つの態様において、R4及びR5は、これらが接続する炭素原子と一緒に選択されて、一つの酸素を有する4員のスピロ複素環を形成する。例えば、実施例6−224の化合物において、R4及びR5は、一つの酸素を有する4員のスピロ複素環式環を形成する:
幾つかの態様において、Lは、所望により置換された二価のC1−6の飽和又は不飽和の、直鎖又は分枝鎖の炭化水素鎖であり、ここにおいて、Lの一つ、二つ、又は三つのメチレン単位は、所望により、そして独立に、−Cy−、−O−、−SO−、−SO2−、−C(O)−、−C(O)N(R)−、−S−、−N(R)−、−C(O)O−、−OC(O)−、−N(R)C(O)−、−N(R)SO2−、又は−SO2N(R)−によって置換される。
幾つかの態様において、Lは:
幾つかの態様において、R6は、所望により置換されたフェニルである。幾つかの態様において、R6は、フェニルである。幾つかの態様において、R6は、−OR、−NO2、−CN、−SR、−N(R)2、−C(O)R、−C(O)OR、−S(O)R、−S(O)2R、−C(O)N(R)2、−S(O)2N(R)2、−OC(O)R、−N(R)C(O)R、−N(R)C(O)OR、−N(R)SO2R、又は−OC(O)N(R)2から選択される一つ又はそれより多い基で置換されたフェニルである。幾つかの態様において、R6は、−CNで置換されたフェニルである。幾つかの態様において、R6は、−OCF3で置換されたフェニルである。
幾つかの態様において、R6は、所望により置換されたピリジル、ピリミジニル、又はピラジニルである。幾つかの態様において、R6は、ピリジルである。幾つかの態様において、R6は、−CN又は−CF3で置換されたピリジルである。幾つかの態様において、R6は、ハロゲンで置換されたピリジルである。幾つかの態様において、R6は、フッ素で置換されたピリジルである。幾つかの態様において、R6は、フッ素及び−CF3で置換されたピリジルである。幾つかの態様において、R6は:
幾つかの態様において、R6は、ハロゲンで置換されたピリミジニルである。幾つかの態様において、R6は、フッ素で置換されたピリミジニルである。幾つかの態様において、R6は、−CF3で置換されたピリミジニルである。幾つかの態様において、R6は、−NH2で置換されたピリミジニルである。
幾つかの態様において、R6は、酸素、窒素、又は硫黄から選択される1−3個の異種原子を有する所望により置換された5員のヘテロアリールである。幾つかの態様において、R6は、酸素、窒素、又は硫黄から選択される2個の異種原子を有する所望により置換された5員のヘテロアリールである。幾つかの態様において、R6は、所望により置換されたチアゾリル又はイミダゾリルである。
幾つかの態様において、R6は、酸素、窒素、又は硫黄から選択される2個の異種原子を有する所望により置換された5員の飽和又は部分的に不飽和の単環式ヘテロシクリルである。幾つかの態様において、R6は、酸素又は窒素から選択される2個の異種原子を有する所望により置換された5員の飽和又は部分的に不飽和の単環式ヘテロシクリルである。幾つかの態様において、R6は、所望により置換されたオキサゾリジニル又はジオキソラニルである。幾つかの態様において、R6は、二つのメチル基で置換されたジオキソラニルである。
幾つかの態様において、R6は、所望により置換された5員の飽和又は部分的に不飽和の単環式カルボシクリルである。幾つかの態様において、R6は、所望により置換されたシクロペンチルである。幾つかの態様において、R6は、シクロペンチルである。
幾つかの態様において、R6は、水素である。
幾つかの態様において、R6は、−ハロゲン、−OR、−NO2、−CN、−SR、−N(R)2、−C(O)R、−C(O)OR、−S(O)R、−S(O)2R、−C(O)N(R)2、−S(O)2N(R)2、−OC(O)R、−N(R)C(O)R、−N(R)C(O)OR、−N(R)S(O)2R、−OC(O)N(R)2、及び所望によりハロゲンで置換されたC1−6脂肪族からなる群から選択される一つ又はそれより多い基で置換される。幾つかの態様において、R6は、メチル、−F、−Cl、−OH、−OCH3、−NH2、−NHCH3、−N(CH3)CH3、−CF3、−CN、−OCF3、−S(O)2CH3、及び−NHS(O)2CH3からなる群から選択される一つ又はそれより多い基で置換される。
幾つかの態様において、R6は、−CF3である。
幾つかの態様において、Lは、共有結合であり、そしてR6は、水素である。
幾つかの態様において、Lは、共有結合であり、そしてR6は、フェニルである。幾つかの態様において、Lは、−CH2−であり、そしてR6は、フェニルである。幾つかの態様において、Lは、−CH2(CH3)−であり、そしてR6はフェニルである。
幾つかの態様において、Lは、共有結合であり、そしてR6は、テトラヒドロピラニルである。幾つかの態様において、Lは、共有結合であり、そしてR6は、テトラヒドロフラニルである。幾つかの態様において、Lは、共有結合であり、そしてR6は、オキセタニルである。
幾つかの態様において、提供される化合物は、以下の式IV:
本発明の化合物を提供する一般的方法
本発明の化合物は、一般的に公知の合成方法の適当な組合せによって合成される。本発明の化合物の合成において有用な技術は、当業者にとって容易に明白であり、そして到達可能の両方である。以下の考察は、本発明の化合物を構築することにおいて使用するために使用可能な多様な方法のあるものを例示するために提供する。然しながら、考察は、本発明の化合物の調製において有用である反応又は反応の配列の範囲を定義することは意図していない。
スキームA
スキームB
ある態様において、本発明の化合物は、医薬において使用するためのものである。幾つかの態様において、本発明の化合物は、寄生虫感染症の治療において有用である。用語“寄生虫感染症”は、寄生虫に関係する疾病又は疾患を含む。幾つかの態様において、“寄生虫感染症”は、寄生虫、例えば、Trypanosoma cruzi、Trypanosoma congolense、Trypanosoma vivax、及びTrypanosoma evansiに関係する疾病又は疾患を含む。
もう一つの側面において、本発明は、式Iの化合物又は医薬的に受容可能な賦形剤(例えば、賦形剤)との組合せにおける式Iの化合物を含んでなる医薬組成物を提供する。
本発明の化合物は、更に、更なる治療剤と併用して用いることができる。従って、本発明は、更なる側面において、本明細書中に記載される化合物又は医薬的に受容可能なその塩を少なくとも一つの更なる治療剤を一緒に含んでなる組合せを提供する。例示的な態様において、更なる治療剤は、本発明の化合物である。例示的な態様において、更なる治療剤は、ホウ素原子を含む。
本発明の化合物は、幅広い各種の経口、非経口、及び局所投与形態で調製し、そして投与することができる。従って、本発明の化合物は、注射(例えば、静脈内、筋肉内、皮内、皮下、十二指腸内、又は腹腔内的に)投与することができる。更に、本明細書中に記載される化合物は、吸入によって、例えば鼻腔内的に投与することができる。更に、本発明の化合物は、経皮的に投与することができる。複数の投与の経路(例えば、筋肉内、経口、経皮)を、本発明の化合物を投与するために使用することができることも更に想定されている。従って、本発明は、更に医薬的に受容可能な担体又は賦形剤及び一つ又はそれより多い本発明の化合物を含んでなる医薬組成物を提供する。
本発明によって提供される医薬組成物は、活性成分が治療的に有効な量で、即ち、その意図する目的を達成するために有効な量で含有される組成物を含む。特定の適用のために有効な実際の量は、特に、治療される症状に依存するものである。例えば、寄生虫感染症の方法において投与される場合、このような組成物は、所望の結果を達成するために有効な活性成分の量を含有するものである。
実施例が、“実施例I−XX”と言及することによってもう一つの実施例に言及する場合、この言及は、それぞれの化合物6−XXの合成、又は合成の関連する部分に対するものであることは認識されるものである。
1H NMR(400MHz,CDCl3)8.01(d,J=8.0Hz,1H),7.16(d,J=8.0Hz,1H),5.30(q,J=6.4Hz,1H),4.38(q,J=7.2Hz,2H),2.80(s,3H),1.52(d,J=6.4Hz,3H),1.41(t,J=7.2Hz,3H)。
工程1: 化合物2(3g、12.3mmol)のDMF(30mL)中の撹拌された溶液に、K2CO3(2.54g、18.4mmol)をRTで加え、そして30分間撹拌した。次いでEtI(2.92mL、36.9mmol)をRTで加え、そして反応混合物をRTで16時間撹拌した。反応の進行をTLCによってモニターした。TLCは出発物質の完全な消費を伴う非極性のスポットの形成を示した。反応混合物を氷冷の水でクエンチし、そしてEtOAc(2×100mL)で抽出した。混合した有機層を水、食塩水で洗浄し、そしてNa2SO4で乾燥した。溶媒を減圧下で除去して、粗製の物質を得た。粗製の化合物をシリカゲルのカラムクロマトグラフィー(100−200メッシュ;石油エーテル中の2−4%EtOAc)によって精製して、化合物3(2.2g、66%)を、無色の液体として得た。1H NMR(300MHz,DMSO−d6):δ 12.6(s,1H),9.25(s,1H),7.72(d,1H),7.10(d,1H),5.02(s,2H),4.32(qt,2H),1.28(t,3H);LC−MS:m/z223.33[M+H]+。
ESI−MS:m/z354[M+H]+;HPLC純度:100%(220nm),100%(254nm)。
ESI−MS m/z416[M+H]+;HPLC純度:100%(220nm),100%(254nm)。
ESI−MS m/z376[M+Na]+;HPLC純度:94.63%(220nm),91.44%(254nm)。
ESI−MS m/z340[M+H]+;HPLC純度:99.08%(220nm),99.48%(254nm)。
ESI−MS m/z434[M+H]+;HPLC純度:98.71%(220nm),96.67%(254nm)。
1H NMR(400MHz,DMSO−d6)9.02(s,1H),8.47(d,J=8.0Hz,1H),7.38(d,J=8.0Hz,1H),7.24(d,J=8.0Hz,1H),4.97(s,2H),4.39−4.36(m,1H),4.23−4.13(m,1H),4.03−3.99(m,1H),3.69−3.65(m,2H),3.39−3.37(m,2H),2.48(s,3H),2.38−2.33(m,1H),0.97−0.95(m,6H);ESI−MS m/z366[M+H]+;HPLC純度:99.66%(220nm),99.63%(254nm)。
HPLC純度:97.28%(220nm),97.90%(254nm)。
実施例163. 4−(2−(ピロリジン−1−イル)エトキシ)ベンジル(1−ヒドロキシ−7−メチル−1,3−ジヒドロベンゾ[c][1,2]オキサボロール−6−カルボニル)−L−バリネート(6−163)
実施例177. ジメチル(1−ヒドロキシ−1,3−ジヒドロベンゾ[c][1,2]オキサボロール−6−カルボニル)−L−アスパルテート(6−177)
実施例178. メチル(1−ヒドロキシ−1,3−ジヒドロベンゾ[c][1,2]オキサボロール−6−カルボニル)−L−ロイシネート(6−178)
実施例179. メチル(1−ヒドロキシ−1,3−ジヒドロベンゾ[c][1,2]オキサボロール−6−カルボニル)−L−バリネート(6−179)
実施例180. メチル(1−ヒドロキシ−1,3−ジヒドロベンゾ[c][1,2]オキサボロール−6−カルボニル)−L−アロイソロイシネート(6−180)
実施例181. メチル(1−ヒドロキシ−1,3−ジヒドロベンゾ[c][1,2]オキサボロール−6−カルボニル)−L−フェニルアラニネート(6−181)
実施例182. メチル(1−ヒドロキシ−1,3−ジヒドロベンゾ[c][1,2]オキサボロール−6−カルボニル)−L−チロシネート(6−182)
実施例183. メチル(1−ヒドロキシ−1,3−ジヒドロベンゾ[c][1,2]オキサボロール−6−カルボニル)−L−トリプトファネート(6−183)
実施例184. メチル(S)−3−シクロプロピル−2−(1−ヒドロキシ−1,3−ジヒドロベンゾ[c][1,2]オキサボロール−6−カルボキシアミド)プロパノエート(6−184)
実施例185. 3,4−ジフルオロベンジル(1−ヒドロキシ−1,3−ジヒドロベンゾ[c][1,2]オキサボロール−6−カルボニル)−L−バリネート(6−185)
LC−MS:m/z383.45[M+H]+.HPLC純度:99.25%(220nm),98.10%(254nm)、そしてキラルHPLC純度は98.92%(210nm)である。
LC−MS:m/z399.25[M+H]+.HPLC純度:93.98%(220nm)、そしてキラルHPLC純度は96.7%(210nm)である。
ESI−MS m/z469[M+H]+;HPLC純度:99.10%(220nm),97.74%(254nm)。
化合物を、IL3000のT.congolense(薬物感受性)株に対する化学療法的効力に対して、幾つかの改変を伴うアラマーブルーアッセイを使用して、in vitroで試験した。試験化合物を、それぞれのアッセイ実行のための10mg/mLのDMSO原液として調製した。化合物を少なくとも3回別個の独立の試験実行で分析し、そして11点の希釈曲線を、IC50値を決定するために使用した。血流型のトリパノソーマを、20%のウシ血清を含有するHMI培地中に支持し、そして試験化合物と共に、5%のCO2を含有する加湿された雰囲気中で96時間34℃でインキュベートした。その後、10μLのレサズリン染料(100mLのリン酸緩衝食塩水中の12.5mg、Sigma−Aldrich,Buchs,Switzerland)を更に3時間加えた。次いでプレートを蛍光プレートリーダー(Spectramax,Gemini XS,Bucher Biotec,Basel,Switzerland)を使用して、536nmの励起波長及び588nmの発光波長を使用して読取った。データの点を平均して、S字型の用量反応曲線を発生し、そしてIC50値をSoftmaxPro5.2ソフトウェアを使用して決定した。
化合物を、STIB719/ILRAD560のT.vivax(薬物感受性)株に対する化学療法的効力に対して、幾つかの改変を伴うアラマーブルーアッセイを使用して、ex vivoで試験した。試験化合物を、それぞれのアッセイ実行のための10mg/mLのDMSO原液として調製した。化合物を少なくとも3回別個の独立の試験実行で分析し、そして11点の希釈曲線を、IC50値を決定するために使用した。血流型のトリパノソーマを、高度に寄生虫血症のマウスから増殖し、そして回収し(心穿刺により)、そして20%のウシ血清を含有するHMI培地中に支持して、試験化合物と共に、5%のCO2を含有する加湿された雰囲気中で45時間37℃でインキュベートした。その後、10μLのレサズリン染料(100mLのリン酸緩衝食塩水中の12.5mg、Sigma−Aldrich,Buchs,Switzerland)を更に3時間加えた。次いでプレートを蛍光プレートリーダー(Spectramax,Gemini XS,Bucher Biotec,Basel,Switzerland)を使用して、536nmの励起波長及び588nmの発光波長を使用して読取った。データの点を平均して、S字型の用量反応曲線を発生し、そしてIC50値をSoftmaxPro5.2ソフトウェアを使用して決定した。
このアッセイに使用されたT.cruzi寄生虫を、遺伝子的に改変して、TdTomato蛍光タンパク質を発現させた。ベロ細胞(アフリカミドリザル腎臓上皮細胞)を、トリプシンを使用する連続培養から回収し、そして96ウェルのGreinerのバイオオープンプレート(プレートカタログ#655090)の内側の60個のウェルに2.5×106細胞/mLで200ul/ウェルで加えた。細胞を1時間付着させてから、T.cruziで感染した。感染のためのT.cruziを、予備感染させたベロ細胞から回収し、洗浄し、ペレット化し、そして5×106/mLで再懸濁した。50uLの寄生虫を、ベロ細胞を含有するそれぞれのウェルに加えた。化合物を、DMSO中の5mMの原液濃度から、5uMから5nMの範囲のウェル中の最終濃度に調製した。ウェルは化合物を欠く負の対照に対して用意した。プレートを37℃のインキュベーターに20分間置き、次いで“0日目”の読取りをSynergyH4プレートリーダーで採取して、544(励起)及び612nm(発光)における初期の蛍光のレベルを記録した。96ウェルプレートを、湿ったペーパータオルを伴うタッパーウェア容器に入れ、そして37℃のインキュベーターで72時間インキュベートとした。72時間後、プレートを再度読取り(3日目の読取り)、そしてデータをExcel及び/又はGraphpadソフトウェアを使用して解析した。1日目の蛍光を3日目から差し引いて、インプットされた寄生虫の蛍光を除去した。増殖曲線を発生し、そして50%及び90%阻害濃度を、非線形回帰分析によって決定した。
本開示はその詳細な説明に関連して記載されてきたが、前記の説明は例示であり、そして付属する特許請求の範囲によって定義される本発明の範囲を制約するものではないことを意図することは理解されるべきである。他の側面、利益、及び改変は、以下の特許請求の範囲の内である。
Claims (21)
- 以下の式I:
R1は、水素又はC1−6脂肪族であり;
R1aは、水素又はC1−6脂肪族であるか;或いは
R1及びR1aは、これらが接続している炭素原子と一緒に選択されて、所望により置換された3−ないし6員のスピロ炭素環式環を形成し;
それぞれのR2は、独立に水素、−ハロゲン、−OR、−NO2、−CN、−SR、−N(R)2、−C(O)R、−C(O)OR、−S(O)R、−S(O)2R、−C(O)N(R)2、−SO2N(R)2、−OC(O)R、−N(R)C(O)R、−N(R)C(O)OR、−N(R)SO2R、−OC(O)N(R)2であるか、又はC1−6脂肪族、及び3−ないし6員の飽和又は部分的に不飽和の単環式カルボシクリルからなる群から選択される所望による置換基であり;
R3は、水素又は所望により置換されたC1−6脂肪族であり;
R4は、水素、天然又は非天然のアミノ酸側鎖基であるか、或いはC1−6脂肪族、3−ないし7員の飽和又は部分的に不飽和の単環式カルボシクリル、及びフェニルからなる群から選択される所望により置換された基であるか;或いは
R3及びR4は、R4に接続した炭素原子及びR3に接続した窒素原子と一緒に選択されて、所望により置換された、酸素、窒素、又は硫黄から選択される0−1個の更なる異種原子を有する3−ないし6員のヘテロシクリルを形成し;
R5は、水素又は所望により置換されたC1−6脂肪族であるか;或いは
R4及びR5は、これらが接続している炭素原子と一緒に選択されて、酸素、窒素、又は硫黄から選択される1−2個の異種原子を有する3−ないし6員のスピロ複素環式環、並びに3−ないし6員の飽和の又は部分的に不飽和の単環式スピロ炭素環式環から選択される、所望により置換された環を形成し;
Lは、共有結合であるか、又は所望により置換された、二価のC1−10飽和又は不飽和の、直鎖又は分枝鎖の炭化水素鎖であり、ここにおいて、Lの一つ、二つ又は三つのメチレン単位は、所望により、そして独立に−Cy−、−O−、−SO−、−SO2−、−C(O)−、−C(O)N(R)−、−S−、−N(R)−、−C(O)O−、−OC(O)−、−N(R)C(O)−、−N(R)SO2−、又は−SO2N(R)−によって置換され;
ここにおいて、それぞれの−Cy−は、フェニレン、3−ないし7員の飽和又は部分的に不飽和の単環式カルボシクリレン、酸素、窒素、又は硫黄から選択される1−2個の異種原子を有する3−ないし7員の飽和又は部分的に不飽和の単環式ヘテロシクリレン、酸素、窒素、又は硫黄から選択される1−4個の異種原子を有する5−ないし6員のへテロアリーレン、7−ないし10員の飽和又は部分的に不飽和の二環式カルボシクリレン、8−ないし10員の二環式アリーレン、酸素、窒素、又は硫黄から選択される1−4個の異種原子を有する7−ないし10員の飽和又は部分的に不飽和の二環式ヘテロシクリレン、及び酸素、窒素、又は硫黄から選択される1−4個の異種原子を有する7−ないし10員の二環式へテロアリーレンからなる群から選択される独立に所望により置換された二価の環であり;
R6は、水素、−ハロゲン、−OR、−NO2、−CN、−SR、−N(R)2、−C(O)R、−C(O)OR、−S(O)R、−S(O)2R、−C(O)N(R)2、−SO2N(R)2、−OC(O)R、−N(R)C(O)R、−N(R)C(O)OR、−N(R)SO2R、−OC(O)N(R)2、C1−6脂肪族、フェニル、酸素、窒素、又は硫黄から選択される1−2個の異種原子を有する3−ないし7員の飽和又は部分的に不飽和の単環式カルボシクリル、酸素、窒素、又は硫黄から選択される1−2個の異種原子を有する3−ないし7員の飽和又は部分的に不飽和の単環式ヘテロシクリル、酸素、窒素、又は硫黄から選択される1−4個の異種原子を有する5−ないし6員のヘテロアリール、
7−ないし10員の飽和又は部分的に不飽和の二環式カルボシクリル、8−ないし10員の二環式アリール、酸素、窒素、又は硫黄から選択される1−4個の異種原子を有する7−ないし10員の飽和又は部分的に不飽和の二環式ヘテロシクリル、酸素、窒素、又は硫黄から選択される1−4個の異種原子を有する7−ないし10員の二環式ヘテロアリール、並びに架橋された二環式からなる群から選択される所望により置換された基であり;
それぞれのRは、独立に水素又は所望により置換されたC1−6脂肪族であり;
ここにおいて、Lが共有結合である場合、R6は、−OR、−ハロゲン、−NO2、−CN、−SR、−N(R)2、−S(O)R、−S(O)2R、−SO2N(R)2、−OC(O)R、−N(R)C(O)R、−N(R)C(O)OR、−N(R)SO2R、又は−OC(O)N(R)2以外であり;そして
ここにおいて、Lが共有結合以外である場合、これは、O*と表示されたカルボキシルの酸素に結合する炭素原子を含む]
の化合物、又は医薬的に受容可能なその塩。 - 化合物が、化合物6−001ないし6−251からなる群から選択される、請求項1に記載の化合物、又は医薬的に受容可能なその塩。
- 化合物が、3,4−ジフルオロベンジル(1−ヒドロキシ−7−メチル−1,3−ジヒドロベンゾ[c][1,2]オキサボロール−6−カルボニル)−L−バリネート;
((S)−テトラヒドロフラン−3−イル)メチル(1−ヒドロキシ−7−メチル−1,3−ジヒドロベンゾ[c][1,2]オキサボロール−6−カルボニル)−L−バリネート;及び
(テトラヒドロ−2H−ピラン−4−イル)メチル(1−ヒドロキシ−7−メチル−1,3−ジヒドロベンゾ[c][1,2]オキサボロール−6−カルボニル)−L−バリネート;
からなる群から選択される、請求項1に記載の化合物、又は医薬的に受容可能なその塩。 - 化合物が、4−フルオロベンジル(1−ヒドロキシ−7−メチル−1,3−ジヒドロベンゾ[c][1,2]オキサボロール−6−カルボニル)−L−バリネートである、請求項1に記載の化合物、又は医薬的に受容可能なその塩。
- 請求項1−17のいずれか1項に記載の化合物を患者に投与することを含んでなる、患者のT.congolense媒介又はT.vivax媒介の疾病又は疾患を治療する方法。
- 疾病又は疾患が、トリパノソーマ症である、請求項18に記載の方法。
- 請求項1−17のいずれか1項に記載の化合物を患者に投与することを含んでなる、患者のT.cruzi媒介の疾病又は疾患を治療する方法。
- 疾病又は疾患が、シャーガス病である、請求項20に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662335565P | 2016-05-12 | 2016-05-12 | |
US62/335,565 | 2016-05-12 | ||
PCT/IB2017/052522 WO2017195069A1 (en) | 2016-05-12 | 2017-05-01 | Oxaborole esters and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019009932A Division JP6715966B2 (ja) | 2016-05-12 | 2019-01-24 | オキサボロールエステル及びその使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019520326A true JP2019520326A (ja) | 2019-07-18 |
JP6715957B2 JP6715957B2 (ja) | 2020-07-01 |
Family
ID=58699201
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018559924A Expired - Fee Related JP6715957B2 (ja) | 2016-05-12 | 2017-05-01 | オキサボロールエステル及びその使用 |
JP2019009932A Expired - Fee Related JP6715966B2 (ja) | 2016-05-12 | 2019-01-24 | オキサボロールエステル及びその使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019009932A Expired - Fee Related JP6715966B2 (ja) | 2016-05-12 | 2019-01-24 | オキサボロールエステル及びその使用 |
Country Status (31)
Country | Link |
---|---|
US (4) | US10562921B2 (ja) |
EP (2) | EP3455227A1 (ja) |
JP (2) | JP6715957B2 (ja) |
KR (2) | KR102243775B1 (ja) |
CN (2) | CN109503637B (ja) |
AR (2) | AR108450A1 (ja) |
AU (2) | AU2017263785B2 (ja) |
BR (2) | BR122018076188A2 (ja) |
CA (1) | CA3023490C (ja) |
CL (2) | CL2018003187A1 (ja) |
CO (1) | CO2018012077A2 (ja) |
CR (2) | CR20180502A (ja) |
DK (1) | DK3578562T3 (ja) |
EA (2) | EA036661B1 (ja) |
EC (2) | ECSP18091065A (ja) |
ES (1) | ES2882782T3 (ja) |
HK (1) | HK1258717A1 (ja) |
HU (1) | HUE056320T2 (ja) |
IL (2) | IL262453A (ja) |
MA (1) | MA44968A (ja) |
MX (2) | MX2018013743A (ja) |
NI (2) | NI201801171A (ja) |
NZ (1) | NZ746906A (ja) |
PE (2) | PE20191077A1 (ja) |
PT (1) | PT3578562T (ja) |
SG (1) | SG11201809237RA (ja) |
TN (2) | TN2018000351A1 (ja) |
TW (1) | TWI629279B (ja) |
UA (2) | UA120999C2 (ja) |
UY (2) | UY37236A (ja) |
WO (1) | WO2017195069A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019081770A (ja) * | 2016-05-12 | 2019-05-30 | アナコール・ファーマシューティカルズ・インコーポレーテッド | オキサボロールエステル及びその使用 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11039617B2 (en) | 2013-01-30 | 2021-06-22 | Agrofresh Inc. | Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness |
US10070649B2 (en) | 2013-01-30 | 2018-09-11 | Agrofresh Inc. | Volatile applications against pathogens |
WO2017155879A1 (en) | 2016-03-07 | 2017-09-14 | Agrofresh Inc. | Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops |
MX2020005464A (es) | 2017-11-30 | 2020-12-03 | Boragen Inc | Compuestos de benzoxaborol y formulaciones de los mismos. |
JP2020180170A (ja) * | 2019-04-23 | 2020-11-05 | 東ソー株式会社 | ハロゲン含有ポリエーテルポリオール組成物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010045503A1 (en) * | 2008-10-15 | 2010-04-22 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-protozoal agents |
WO2010045505A1 (en) * | 2008-10-15 | 2010-04-22 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules as anti-protozoal agents |
WO2015097276A1 (en) * | 2013-12-23 | 2015-07-02 | Syngenta Participations Ag | Benzoxaborole fungicides |
JP2019081770A (ja) * | 2016-05-12 | 2019-05-30 | アナコール・ファーマシューティカルズ・インコーポレーテッド | オキサボロールエステル及びその使用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
GB9411587D0 (en) | 1994-06-09 | 1994-08-03 | Zeneca Ltd | Compound, composition and use |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
JO3396B1 (ar) | 2007-06-20 | 2019-10-20 | Anacor Pharmaceuticals Inc | جزيئات صغيرة تحتوي على البورون |
WO2011019618A1 (en) | 2009-08-14 | 2011-02-17 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
ES2582471T3 (es) | 2011-02-07 | 2016-09-13 | Rempex Pharmaceuticals, Inc. | Inhibidores polibásicos de la bomba de flujo de salida bacteriana que contienen boro y usos terapéuticos de los mismos |
BR112014008186A2 (pt) | 2011-10-07 | 2017-04-11 | Syngenta Participations Ag | método para proteção de plantas úteis ou material de propagação de plantas |
AR088669A1 (es) | 2011-11-21 | 2014-06-25 | Lilly Co Eli | Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos |
US8669207B1 (en) * | 2013-01-30 | 2014-03-11 | Dow Agrosciences, Llc. | Compounds and compositions |
WO2015013318A1 (en) | 2013-07-22 | 2015-01-29 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
CN105492388B (zh) | 2013-08-09 | 2018-12-21 | 葛兰素史克知识产权第二有限公司 | 三环苯并氧杂硼杂环戊烯化合物及其用途 |
US20180244699A1 (en) * | 2015-08-17 | 2018-08-30 | Syngenta Participations Ag | 1-hydroxy-3h-2,1-benzoxaborole derivatives and their use as microbiocides |
-
2017
- 2017-05-01 KR KR1020187035848A patent/KR102243775B1/ko active IP Right Grant
- 2017-05-01 CA CA3023490A patent/CA3023490C/en active Active
- 2017-05-01 SG SG11201809237RA patent/SG11201809237RA/en unknown
- 2017-05-01 EA EA201892475A patent/EA036661B1/ru not_active IP Right Cessation
- 2017-05-01 WO PCT/IB2017/052522 patent/WO2017195069A1/en active Application Filing
- 2017-05-01 EP EP17722886.3A patent/EP3455227A1/en not_active Withdrawn
- 2017-05-01 BR BR122018076188A patent/BR122018076188A2/pt not_active Application Discontinuation
- 2017-05-01 ES ES19180969T patent/ES2882782T3/es active Active
- 2017-05-01 CN CN201811522724.7A patent/CN109503637B/zh active Active
- 2017-05-01 UA UAA201810456A patent/UA120999C2/uk unknown
- 2017-05-01 PT PT191809698T patent/PT3578562T/pt unknown
- 2017-05-01 JP JP2018559924A patent/JP6715957B2/ja not_active Expired - Fee Related
- 2017-05-01 PE PE2019000887A patent/PE20191077A1/es unknown
- 2017-05-01 NZ NZ746906A patent/NZ746906A/en not_active IP Right Cessation
- 2017-05-01 CN CN201780029103.2A patent/CN109153688A/zh active Pending
- 2017-05-01 MA MA044968A patent/MA44968A/fr unknown
- 2017-05-01 KR KR1020187035855A patent/KR102231489B1/ko active IP Right Grant
- 2017-05-01 MX MX2018013743A patent/MX2018013743A/es unknown
- 2017-05-01 BR BR122023022427-2A patent/BR122023022427A2/pt unknown
- 2017-05-01 AU AU2017263785A patent/AU2017263785B2/en not_active Ceased
- 2017-05-01 CR CR20180502A patent/CR20180502A/es unknown
- 2017-05-01 TN TNP/2018/000351A patent/TN2018000351A1/en unknown
- 2017-05-01 CR CR20180560A patent/CR20180560A/es unknown
- 2017-05-01 EP EP19180969.8A patent/EP3578562B1/en active Active
- 2017-05-01 UA UAA201811418A patent/UA121354C2/uk unknown
- 2017-05-01 EA EA201892203A patent/EA034415B1/ru unknown
- 2017-05-01 TN TNP/2019/000106A patent/TN2019000106A1/en unknown
- 2017-05-01 HU HUE19180969A patent/HUE056320T2/hu unknown
- 2017-05-01 PE PE2018002055A patent/PE20190119A1/es unknown
- 2017-05-01 DK DK19180969.8T patent/DK3578562T3/da active
- 2017-05-09 TW TW106115364A patent/TWI629279B/zh not_active IP Right Cessation
- 2017-05-09 US US15/590,159 patent/US10562921B2/en active Active
- 2017-05-10 UY UY0001037236A patent/UY37236A/es unknown
- 2017-05-11 AR ARP170101250A patent/AR108450A1/es unknown
-
2018
- 2018-10-17 IL IL262453A patent/IL262453A/en unknown
- 2018-11-08 CO CONC2018/0012077A patent/CO2018012077A2/es unknown
- 2018-11-09 MX MX2018015410A patent/MX2018015410A/es unknown
- 2018-11-09 NI NI2018001171A patent/NI201801171A/es unknown
- 2018-11-09 CL CL2018003187A patent/CL2018003187A1/es unknown
- 2018-11-09 NI NI2018001172A patent/NI201801172A/es unknown
- 2018-11-16 AU AU2018264116A patent/AU2018264116B2/en not_active Ceased
- 2018-11-20 IL IL263161A patent/IL263161B/en unknown
- 2018-11-22 UY UY0001037980A patent/UY37980A/es unknown
- 2018-11-23 AR ARP180103435A patent/AR113543A2/es unknown
- 2018-11-27 CL CL2018003377A patent/CL2018003377A1/es unknown
- 2018-12-11 EC ECSENADI201891065A patent/ECSP18091065A/es unknown
-
2019
- 2019-01-22 HK HK19101118.4A patent/HK1258717A1/zh unknown
- 2019-01-24 JP JP2019009932A patent/JP6715966B2/ja not_active Expired - Fee Related
- 2019-04-12 EC ECSENADI201926702A patent/ECSP19026702A/es unknown
- 2019-09-24 US US16/580,676 patent/US10882872B2/en active Active
-
2020
- 2020-12-01 US US17/108,066 patent/US11578087B2/en active Active
-
2022
- 2022-12-22 US US18/145,315 patent/US20230132298A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010045503A1 (en) * | 2008-10-15 | 2010-04-22 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-protozoal agents |
WO2010045505A1 (en) * | 2008-10-15 | 2010-04-22 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules as anti-protozoal agents |
WO2015097276A1 (en) * | 2013-12-23 | 2015-07-02 | Syngenta Participations Ag | Benzoxaborole fungicides |
JP2019081770A (ja) * | 2016-05-12 | 2019-05-30 | アナコール・ファーマシューティカルズ・インコーポレーテッド | オキサボロールエステル及びその使用 |
Non-Patent Citations (5)
Title |
---|
ACS MED. CHEM. LETT., vol. 1, JPN6019043450, 2010, pages 165 - 169, ISSN: 0004150468 * |
CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 16, JPN6019043451, 2016, pages 2245 - 2265, ISSN: 0004150469 * |
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 109, JPN6019043454, 2016, pages 173 - 186, ISSN: 0004150472 * |
J. CHEM. INF. MODEL., vol. 53, JPN6019043453, 2013, pages 2402 - 2408, ISSN: 0004150471 * |
MAR. DRUGS, vol. 11, JPN6019043452, 2013, pages 3472 - 3499, ISSN: 0004150470 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019081770A (ja) * | 2016-05-12 | 2019-05-30 | アナコール・ファーマシューティカルズ・インコーポレーテッド | オキサボロールエステル及びその使用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6715966B2 (ja) | オキサボロールエステル及びその使用 | |
CN104136411B (zh) | 治疗活性化合物及其使用方法 | |
CN105358550B (zh) | 组蛋白脱乙酰基酶抑制剂 | |
CN104507928B (zh) | 脂质合成的杂环调节剂 | |
ES2540052T3 (es) | Inhibidores del virus de la hepatitis C | |
TW201040160A (en) | Hepatitis C virus inhibitors | |
CN105992759A (zh) | 1,2-萘醌的衍生物及其制备方法 | |
OA19270A (en) | Oxaborole esters and uses thereof. | |
OA19222A (en) | Oxaborole esters and uses thereof. | |
EP4011874A1 (en) | Substituted pyrazolo piperidine carboxylic acids | |
BR112018071931B1 (pt) | Ésteres de oxaborol e usos dos mesmos | |
WO2009128262A1 (ja) | キノロン誘導体およびその用途 | |
TW202342060A (zh) | Lonp1抑制劑化合物、用途及方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190124 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190124 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191031 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20191111 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200330 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200511 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200609 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6715957 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |